Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group. The company said on Monday that it would stop ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...